Cardiovascular Systems — Corporate Update (September 2019)
24 slides from Cardiovascular Systems's corporate update, Sep 26, 2019
Slide 1: Product Pipeline Update
Cardiovascular Systems, Inc. Product Pipeline Update September 26, 2019 ©2019 Cardiovascular Systems, Inc. All Rights Reserved.
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r
Slide 3: Introduction
Introduction Scott R. Ward, Chairman, President & Chief Executive Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 3
Slide 4: Driving Sustainable Growth
Driving Sustainable Growth Broaden Our Value Streams Financial Goal: FY19-FY23 CAGR of 15% - 18% Revenue of $435M - $500M in FY23 Grow and Protect Innovation Drives Global Expansion Accelerates the Core Business Incremental Growth Growth of Core Business Sustain Market Leadership Launch 20+ New Prod
Slide 5: Fiscal 2019 Revenue Growth of 14.3%
Fiscal 2019 Revenue Growth of 14.3% $248 Million New Product Revenue $3.9 million Core OAS Revenue $236.2 million Drivers 10% increase Sapphire II 1.0 mm PTCA Teleport Microcatheter Zilient Peripheral Guidewire International Revenue $7.9 million Drivers Launched OAS in 10 New countries Product, Over
Slide 6: Portfolio Update
Portfolio Update Rhonda J. Robb, Chief Operating Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 6
Slide 7: Current Market Dynamics Favor Innovation
Current Market Dynamics Favor Innovation Large Under-Served and Under-Treated Disease States Peripheral Artery Disease Coronary Artery Disease Growing proportion of coronary Significantly under-diagnosed and interventions represented by complex under-treated patient populations or complex high-risk
Slide 8: Diversification Accelerates Growth
Diversification Accelerates Growth Broadens Value Streams CSI’s Addressable Markets (US) ~$3.7B Hemodynamic Support Interventional Support Devices Atherectomy Portfolio expansion will drive a >4X increase in CSI’s addressable market $650M FY19 FY23 • Millennium Research Group (2018 December) Medtech
Slide 9: Differentiated Pipeline of Key Value Drivers
Differentiated Pipeline of Key Value Drivers Supports Diversified and Sustainable Growth FY19 FY23 FY23 Growth / Value Drivers Portfolio Market Market TAM FY20 FY21/22 FY23+ • CAD ViperWire Advance with • Next gen Coronary OAS Flex Tip • ECLIPSE • PAD Directional Atherectomy • Peripheral Diamondback
Slide 10: Peripheral
Peripheral ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 10
Slide 11: Radial is a Core Competitive Advantage
Radial is a Core Competitive Advantage Enabling a Complete Peripheral Intervention from the Radial Artery Launched Q2 FY19 Launched Q1 FY19 Expected Launch Early FY21 Exclusive route of access for CSI complementary to tibial/pedal Extended length Extended length Radial Expansion in portfolio of Exch
Slide 12: Supporting Complete Leg Revascularization
Supporting Complete Leg Revascularization Exchangeable Series with GlideAssist® – Our Most Advanced OAS on the Market GlideAssist to facilitate tracking, repositioning and removal of OAD through challenging anatomy Ease-of-Use Enhancements to Handle: Backloadable system facilitating easier wire exch
Slide 13: Exchangeable is a Competitive Advantage
Exchangeable is a Competitive Advantage Exchangeable Series OAS live case, including feature of Teleport® Microcatheter and Zilient® Guidewire Dr. Fadi Saab, Amputation Prevention Symposium, August 14, 2019 13
Slide 14: Compelling Clinical Evidence Supporting Atherectomy
Compelling Clinical Evidence Supporting Atherectomy; OAS Short- and Long-Term Safety Atherectomy provides a benefit for CLI Surgical bypass-first treatment was patients—in this study, there were lower associated with worse amputation free rates of 4-year major amputation and survival (AFS) compared
Slide 15: Directional Atherectomy
Directional Atherectomy Expanding the Treatment Options for Soft and Fibrotic Mixed Plaque Lesions Broaden value streams in a $300M-$400M existing ATK atherectomy market Extend CSI’s peripheral atherectomy toolkit to Deliver novel cutter design to improve lesion entry, engagement, and treatment, wit
Slide 16: WIRION Embolic Protection System
WIRION® Embolic Protection System Supporting Our Commitment to Complex Patients Protecting Patients During PVIs Share-Taking Differentiated Technology Embolic debris can be associated with all types of peripheral vascular intervention procedures EPDs are typically used when treating vessels located
Slide 17: Coronary
Coronary ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 17
Slide 18: Near-Term Expansion of the Complex Coronary Toolkit
Near-Term Expansion of the Complex Coronary Toolkit Drives Incremental Revenue Opportunity Per Case Launched FY19 Launched FY19 Expected Launches FY20 Adding Essentials of the Complex PCI Toolkit • Sapphire SC II PRO 1.0-4.0mm • Sapphire SC II PRO 1.0mm OTW • Sapphire NC Plus 2.0-4.0mm • Sapphire NC
Slide 19: ECLIPSE Trial
ECLIPSE Trial Generating Level One Evidence to Impact Guidelines Patients with Severely 2000 Primary Endpoints Calcified Lesions Randomize 1:1 Orbital Atherectomy Strategy Conventional Angioplasty Strategy ~500 subjects in OCT cohort 1.25 mm Classic Crown followed by Conventional and/or specialty ba
Slide 20: Percutaneous Ventricular Assist Device (pVAD) System
Percutaneous Ventricular Assist Device (pVAD) System Multi-Generational Platform Highly Synergistic with Our Strategy and Competency Generation 1 Overview Entering a High Growth pVAD Market* $1,800 $1,500 16% CAGR $1,200 $900 • Leverages CSI core Millions $ $600 competency in motor control and spinn
Slide 21: Closing Remarks
Closing Remarks Scott R. Ward, Chairman, President & Chief Executive Officer ©2019 Cardiovascular Systems, Inc. All Rights Reserved. 21
Slide 22: Platform for Growth
Platform for Growth Maintain focus on current customer, vessel preparation and procedure support Organic growth and opportunistic portfolio management ~$250M Gross margins in the range of 78%-80% in FY19-FY23 FY21 R&D Investments R&D investments increase to 14%-17% of revenues in FY21 Launch 20 new
Slide 23: Driving Sustainable Long-Term Growth
Driving Sustainable Long-Term Growth Product Launches FY19 - FY23 Revenue Growth FY19 FY20 FY21-FY23 5 - Year CAGR: 15% – 18% • Radial OAS • Exchangeable OAS • Radial toolkit • Peripheral • Next generation • Scoring balloons Guidewires OAS with • WIRION embolic $340M - $350M • ViperCath XC GlideAssi
Slide 24: Creating Shareholder Value
Cardiovascular Systems, Inc. Creating Shareholder Value Financially Strong Leveraging a A Compelling Creating with the Team and Strong Core Business Growth Strategy Competitive Advantage Talent to Win Sustaining double digit Improving outcomes for Driving market leading Highest quality growth comple
Cardiovascular Systems — Corporate Update (September 2019) on 6ix